Clorox (NYSE: CLX) shares edged lower on Tuesday, closing at $105.55, a decline of 0.37%, as investors weighed the impact of a lettuce-related illness outbreak on the company's Hidden Valley Ranch dressing sales. The stock's modest dip reflects concerns that the outbreak could further pressure the consumer products giant's already slim organic growth prospects.
Hidden Valley Sales Hit by Outbreak
According to Nielsen data cited by TD Cowen, sales of Hidden Valley dressing fell 5% over the four weeks ended mid-August. This decline is directly tied to the ongoing lettuce recall linked to Taylor Farms de Mexico, which has been removed from store shelves. The FDA reported 9,481 confirmed illnesses across 17 states as of August 13, a 49% increase from the 6,358 cases reported on August 5. Hospitalizations rose 43% to 398, while the death toll remained unchanged at two.
Hidden Valley dressings account for roughly 11% of Clorox's U.S. retail revenue. Applying that proportion to the 5% sales decline results in an estimated 0.55% drag on the company's total U.S. retail sales, assuming no other changes. This preliminary estimate, based on TD Cowen's analysis, highlights the potential financial impact of the outbreak on Clorox's top line.
Comparison with Kraft Heinz
The impact on Clorox is more pronounced than on Kraft Heinz (NASDAQ: KHC), which also sells dressings. Kraft Heinz's dressing sales declined 20% over the same period, but dressings represent only about 2% of its U.S. retail sales. As a result, the implied drag on Kraft Heinz's overall U.S. retail sales is just 0.40%, less than Clorox's 0.55% despite the faster decline rate.
TD Cowen analyst Robert Moskow expects consumer confidence and sales to recover gradually as the outbreak subsides. However, he cautioned that the timing could be significant, given Clorox's need for organic growth following a lackluster fiscal year. The FDA noted that confirmations often trail the onset of symptoms, so demand may recover before case counts peak.
Clorox's Financial Position
Clorox enters this challenge with narrow margins. For fiscal 2026, net sales declined 5% to $6.72 billion, while organic sales fell 8%. The lifestyle segment, which includes Hidden Valley, saw revenue drop 14% to $1.12 billion. The company's gross margin stood at 42.3%, and adjusted earnings per share came in at $5.53.
Looking ahead to fiscal 2027, management guided for net sales growth of 13% to 14%, but this headline figure is inflated by acquisitions and favorable ERP comparisons. Organic sales are expected to grow just 3.5% to 4.5%, with the ERP comparison adding over 3.5 points. Adjusted EPS is projected to be between $5.70 and $6.00, an increase of 3% to 8%.
However, the organic growth outlook is thin, and ongoing weakness at Hidden Valley could erode that buffer. The lettuce outbreak adds another layer of uncertainty to Clorox's recovery efforts.
Wall Street Sentiment
Wall Street remains cautious on Clorox. Following the company's earnings report on August 4, five analysts issued price targets with an average of $102.20, about 3.2% below Tuesday's closing price. Targets ranged from JPMorgan's $95 (Underweight) to RBC Capital's $110 (Sector Perform). UBS set a Neutral rating with a $105 target, while Wells Fargo and Evercore ISI had targets of $102 and $99, respectively.
Investors should note that the 0.55% figure is not an official company forecast. Nielsen retail data may exclude certain channels, and a four-week period does not necessarily reflect a quarterly run rate. If consumer confidence rebounds quickly, the drag could be significantly reduced.
Weekly Hidden Valley sales data will be a key indicator to watch. An improvement would support management's recovery narrative, but if sales remain around negative 5% for another month, the outbreak could have a clear impact on first-quarter earnings.
As of 4:00 p.m. EDT on August 18, 2026, Clorox shares were down 0.37% for the day, but up 5.3% year-to-date. The stock's 52-week range is $84.70 to $128.90, and it offers a dividend yield of 5.2%.
